EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells
Enhancer of Zeste Homolog 2 (EZH2) inhibitors (EZH2i) are approved to treat certain cancer types. Previous studies have suggested the potential to combine EZH2i with immune checkpoint blockade targeting coinhibitory receptors like PD-(L)1 and CTLA-4, but whether it can also enhance the activity of a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Frontiers Media S.A.
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/b009c34667ac4334bd59e24939d35690 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|